Friday, May 1, 2026

Coupang’s Bold Lobbying: How a Little-Known Korean E-Commerce Giant Influences U.S. Politics

Coupang's lobbying in the U.S. influences trade relations amid investigations into a data breach, raising concerns over digital discrimination.

Military “North Korea Cruise Missile Launch, Act That Hinders Korean Peninsula Peace Stability”

North Korea's missile drills and submarine developments threaten regional stability, prompting South Korea to call for dialogue and peace efforts.

Heightened Security at Political Rally Following Trump Incident

South Korean authorities increased police presence at the convention for the ruling People Power Party (PPP).

Tag: obesity

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

D&D Pharmatech signs $1.24 million obesity drug research deal with Pfizer

D&D Pharmatech partners with Pfizer for a $1.24M obesity treatment project, marking a significant revenue milestone for the company.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

Sam Chun Dang Pharm Signs 100 Million USD Licensing Deal for Oral Generics of Rybelsus and Wegovy

Sam Chun Dang Pharm secures a U.S. licensing deal for generic diabetes and obesity medications, valued at $100 million.

Inventage Lab Secures 985 Billion KRW: What This Means for Long-Lasting Injection Solutions

Inventage Lab secures 985 billion KRW to enhance its drug delivery platform, focusing on long-acting injectables for obesity and more.

GLP-1 Weight Loss Injections: Are They Causing Gallstone Surge in Asia?

GLP-1 obesity treatments are linked to increased gallstone risk, especially during rapid weight loss, with cases doubling in South Korea.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

How a 2-Cent Sugar Tax Could Save $4.5 Billion in Healthcare Costs: California’s Bold Move

A sugar-sweetened beverage tax in California could cut obesity cases and save $4.5 billion in healthcare costs over ten years.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

Dark Skin Patches in Teens? It Could Be a Warning Sign, Doctors Say

Dark patches on skin folds in adolescents may indicate Acanthosis Nigricans, linked to obesity and insulin resistance. Consult a specialist.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.